Objective: To replicate the beneficial effect of brain-derived neurotrophic factor (BDNF) in
1,135 ALS patients in a multicenter trial. Background: In a phase I through II study, BDNF …

We analyzed data from the 245-patient placebo group of the ALS CNTF Treatment Study
Group study, a large, prospective, multicenter study of recombinant human ciliary …

This pilot study aimed at exploring the effects of intrathecally administered brain derived
neurotrophic factor (BDNF) on autonomic functions in patients with ALS. A battery of …

Background: TCH346 exerts antiapoptotic effects by binding to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and blocking the apoptotic pathway in which GAPDH is involved …

BACKGROUND: Brain derived neurotrophic factor (BDNF) is a potent survival factor for
motoneurons. This study investigated the safety and tolerability of recombinant methionyl (r …

Background: The survival of motor neurons is dependent upon neurotrophic factors both
during childhood and adolescence and during adult life. In disease conditions, such as in …

The objective of this study was to investigate the safety and efficacy of recombinant human
insulinlike growth factor-I (rhIGF-I) in the treatment of sporadic ALS. A double-blind, placebo …

Cerebrospinal fluid from 15 patients with ALS and 11 controls without neurological disease
were analysed for levels of the neurotrophic factors BDNF and GDNF. Analyses were …

The authors calculated the progression rate (ΔFS) using the total revised ALS Functional
Rating Scale (ALSFRS-R) and symptom duration at diagnosis in 82 Japanese patients with …

Objective: To determine whether the Amyotrophic Lateral Sclerosis Functional Rating Scale–
revised (ALSFRSr), a predictor of survival time in ALS clinical trials, predicts survival time in …